Naris Nilubol
National Cancer Institute (NCI)
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Naris Nilubol as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 07:54 UTC. Open this list on ClinicalTrials.gov
- Ph1NCT06487481 · Study of Preoperative Radiation Therapy in Participants With Resectable Recurrent Abdominal Adrenocortical CarcinomaNational Cancer Institute (NCI) · recruiting · Adrenocortical Carcinoma (ACC), Recurrent Adrenocortical Carcinoma (ACC), Recurrent Abdominal Adrenocortical Carcinoma (ACC) · principal investigator
- Ph2NCT04074135 · Natural History and Management of Von Hippel-Lindau (VHL) Associated Pancreatic Neuroendocrine TumorsNational Cancer Institute (NCI) · recruiting · VHL Pancreatic Neuroendocrine Tumors, Von Hippel-Lindau Disease, Neuroendocrine Tumors · principal investigator
- Ph2NCT03002623 · CUDC-907 Treatment in People With Metastatic and Locally Advanced Thyroid CancerNational Cancer Institute (NCI) · terminated · Thyroid Neoplasms, Poorly Differentiated and Undifferentiated Thyroid Cancer, Differentiated Thyroid Cancer · principal investigator
- Ph2NCT02408887 · Total Thyroidectomy With and Without Prophylactic Central Neck Lymph Node Dissection in People With Low-risk Papillary Thyroid CancerNational Cancer Institute (NCI) · terminated · Low-risk Papillary Thyroid Cancer, Endocrine Malignancy, Thyroid Cancer · principal investigator
- Ph2NCT02315625 · Study of Mutation-Targeted Therapy With Sunitinib or Everolimus in People With Advanced Low- or Intermediate-Grade Neuroendocrine Tumors of the Gastrointestinal Tract and Pancreas With or Without Cytoreductive SurgeryNational Cancer Institute (NCI) · terminated · Neuroendocrine Tumors, Neuroendocrine Carcinoma, Neuroendocrine Neoplasms · principal investigator
- Ph2NCT01967537 · Evaluation of 68Gallium-DOTATATE PET/CT for Detecting Neuroendocrine TumorsNational Cancer Institute (NCI) · completed · Neuroendocrine Tumors, Von Hippel-Lindau Syndrome, Hippel-Lindau Disease · principal investigator
- N/ANCT01348698 · Evaluation of Molecular Markers in Adrenal TumorsNational Cancer Institute (NCI) · terminated · Adrenal Gland Neoplasms · principal investigator
- Ph2NCT01182285 · A Phase II Trial of Valproic Acid in Patients With Advanced Thyroid Cancers of Follicular Cell OriginNational Cancer Institute (NCI) · completed · Thyroid Neoplasm · principal investigator
- N/ANCT01005654 · Prospective Comprehensive Molecular Analysis of Endocrine NeoplasmsNational Cancer Institute (NCI) · recruiting · Endocrine Tumors, Thyroid Neoplasms, Parathyroid Neoplasms · principal investigator
- N/ANCT00062166 · Natural History and Management of Pancreatic Lesions in Von Hippel-Lindau DiseaseNational Cancer Institute (NCI) · completed · Von Hippel-Lindau Disease · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 07:54 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Therapeutic targets and novel anticancer agents for endocrine cancersZIABC011286 · NCI · DIVISION OF BASIC SCIENCES - NCI · fiscal years 2019 to 2025 · $926,461 awarded in 2025Same name and institution; not confirmed by an ID
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 07:54 UTC. The ranking covers the 200 most relevant of 7 PubMed records, and a shared surname and initials can bring in a namesake. All 7 on PubMed
- Clonal Evolution and Heterogeneity of Osimertinib Acquired Resistance Mechanisms in EGFR Mutant Lung Cancer.Cell Rep Med · 2020173 citationsRCR 6.0
- A phase II trial of valproic acid in patients with advanced, radioiodine-resistant thyroid cancers of follicular cell origin.Clin Endocrinol (Oxf) · 201750 citationsRCR 1.8
- 45 citationsRCR 1.6
- 23 citationsRCR 0.8
- MicroRNA-210 May Be a Preoperative Biomarker of Malignant Pheochromocytomas and Paragangliomas.J Surg Res · 201918 citationsRCR 0.8
- 13 citationsRCR 0.5
- A feasibility double-blind trial of levothyroxine vs. levothyroxine-liothyronine in postsurgical hypothyroidism.Front Endocrinol (Lausanne) · 20256 citationsRCR 2.8